Jones Hill Capital
Latest statistics and disclosures from Jones Hill Capital's latest quarterly 13F-HR filing:
- Central Index Key (CIK): 0002102314
Tip: Access up to 7 years of quarterly data
Positions held by Jones Hill Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Jones Hill Capital
Jones Hill Capital holds 26 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| BioMarin Pharmaceutical (BMRN) | 15.4 | $72M | 1.3M | 56.49 |
|
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 10.4 | $49M | 109k | 446.54 |
|
|
| Vaxcyte (PCVX) | 8.0 | $38M | 645k | 58.11 |
|
|
| Nuvalent Inc-a (NUVL) | 6.6 | $31M | 301k | 102.45 |
|
|
| Capricor Therapeutics Com New (CAPR) | 5.9 | $28M | 909k | 30.40 |
|
|
| Terns Pharmaceuticals (TERN) | 5.9 | $28M | 521k | 52.72 |
|
|
| Bicara Therapeutics (BCAX) | 5.4 | $25M | 1.3M | 19.89 |
|
|
| Biosante Pharmaceuticals (ANIP) | 5.3 | $25M | 319k | 76.90 |
|
|
| Ultragenyx Pharmaceutical (RARE) | 5.2 | $24M | 1.2M | 20.95 |
|
|
| Enliven Therapeutics (ELVN) | 5.0 | $23M | 593k | 39.20 |
|
|
| Amylyx Pharmaceuticals (AMLX) | 4.8 | $22M | 1.6M | 13.90 |
|
|
| Argenx Se Sponsored Adr (ARGX) | 4.1 | $19M | 26k | 730.25 |
|
|
| Fulcrum Therapeutics (FULC) | 2.9 | $14M | 1.8M | 7.67 |
|
|
| Vir Biotechnology (VIR) | 2.3 | $11M | 1.2M | 8.96 |
|
|
| Nuvation Bio Com Cl A (NUVB) | 2.2 | $10M | 2.4M | 4.29 |
|
|
| Oruka Therapeutics (ORKA) | 1.5 | $6.9M | 141k | 49.05 |
|
|
| Contineum Therapeutics Cl A (CTNM) | 1.4 | $6.7M | 513k | 13.06 |
|
|
| Veradermics Common Stock | 1.4 | $6.4M | 101k | 63.15 |
|
|
| Tonix Pharmaceuticals Hldg C Com New (TNXP) | 1.3 | $6.2M | 452k | 13.75 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 1.0 | $4.8M | 101k | 48.20 |
|
|
| Entrada Therapeutics (TRDA) | 1.0 | $4.7M | 374k | 12.62 |
|
|
| Pharvaris N V (PHVS) | 1.0 | $4.7M | 167k | 28.25 |
|
|
| Trevi Therapeutics (TRVI) | 0.9 | $4.4M | 370k | 11.93 |
|
|
| Relmada Therapeutics (RLMD) | 0.5 | $2.4M | 343k | 6.96 |
|
|
| Silence Therapeutics Ads (SLN) | 0.3 | $1.6M | 302k | 5.27 |
|
|
| Arrivent Biopharma (AVBP) | 0.2 | $1.1M | 46k | 23.07 |
|
Past Filings by Jones Hill Capital
SEC 13F filings are viewable for Jones Hill Capital going back to 2026
- Jones Hill Capital 2026 Q1 filed May 14, 2026